Fangzhou Inc

Novo Nordisk and Fangzhou have launched Kyinsu, the world's first once-weekly basal insulin/GLP-1 RA combination therapy, in China through Fangzhou's AI-driven Internet hospital. The launch expands Novo Nordisk's presence in China by pairing a new treatment format with a digital care platform, targeting broader access for people living with diabetes. The partnership may influence how Novo Nordisk allocates capital between traditional channels and online care in large markets, while also testing a go-to-market model that ties the drug to a digital ecosystem for diagnosis, titration, adherence, and follow-up at scale. Analysts flag potential earnings pressure from competition and pricing, as well as operational and regulatory risks tied to the partner's AI and Internet-hospital infrastructure. Investors may watch how quickly Kyinsu uptake builds on Fangzhou's platform and whether Novo Nordisk extends similar digital-first launches to other products or markets.